Mepolizumab for eosinophilic chronic obstructive pulmonary disease
Patients with chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype may benefit from treatment with mepolizumab, a monoclonal antibody directed against interleukin-5.We performed two phase 3, randomized, placebo-controlled, double-blind, parallel-group trials comparing mepolizu...
Հիմնական հեղինակներ: | Pavord, I, Chanez, P, Criner, G, Kerstjens, H, Korn, S, Lugogo, N, Martinot, J, Sagara, H, Albers, F, Bradford, E, Harris, S, Mayer, B, Rubin, D, Yancey, S, Sciurba, F |
---|---|
Ձևաչափ: | Journal article |
Լեզու: | English |
Հրապարակվել է: |
Massachusetts Medical Society
2017
|
Նմանատիպ նյութեր
-
Late breaking abstract - Dose-ranging study of mepolizumab in eosinophilic COPD
: Pavord, I, և այլն
Հրապարակվել է: (2017) -
Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of METREX and METREO Exacerbation Endpoints
: Bafadhel, M, և այլն
Հրապարակվել է: (2018) -
Mepolizumab for eosinophilic COPD
: Sciurba, F, և այլն
Հրապարակվել է: (2018) -
Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease
(COPD): A Meta-Analysis of METREX and METREO Patient-Reported
Outcomes, Response to Therapy and Lung Function
: Chapman, K, և այլն
Հրապարակվել է: (2018) -
Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.
: Gunsoy, N, և այլն
Հրապարակվել է: (2017)